Sign up to save your podcasts
Or
Share Zepbound vs Wegovy: A two horse race
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Zepbound vs Wegovy: A two horse race
Last week, the FDA approved Eli Lilly's obesity drug Zepbound, creating an anticipated intense competition between it and Novo Nordisk's Wegovy. BioSpace's Greg Slabodkin, Tyler Patchen and Lori Ellis discuss the weight loss race and the future of this drug class.
Plus, a quick recap on Valneva, the FDA's first Chikungunya vaccine approval.
View all episodes
By BioSpace
4.9
1313 ratings
Last week, the FDA approved Eli Lilly's obesity drug Zepbound, creating an anticipated intense competition between it and Novo Nordisk's Wegovy. BioSpace's Greg Slabodkin, Tyler Patchen and Lori Ellis discuss the weight loss race and the future of this drug class.
Plus, a quick recap on Valneva, the FDA's first Chikungunya vaccine approval.
More shows like BioSpace
View all
This American Life
90,841 Listeners
Planet Money
30,814 Listeners
Hidden Brain
43,719 Listeners
Marketplace
8,760 Listeners
Exchanges
954 Listeners
WSJ What’s News
4,362 Listeners
Bloomberg Surveillance
1,176 Listeners
Odd Lots
1,971 Listeners
Up First from NPR
56,879 Listeners
The Indicator from Planet Money
9,572 Listeners
The Readout Loud
323 Listeners
The Journal.
6,072 Listeners
Short Wave
6,564 Listeners
BioCentury This Week
34 Listeners
Biotech Hangout
21 Listeners